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Purpose:	 PD-L1	 expression	 determination	 defines	 eligibility	 for	 treatment	with	




status	 on	 whole	 sections	 and	 how	 many	 biopsies	 are	 needed	 for	 confident	
classification	of	tumors	in	terms	of	PD-L1	expression.	
Materials	 and	 Methods:	 we	 built	 tissue	 microarrays	 as	 surrogate	 of	 biopsies	
collecting	5	cores	per	case	from	268	cases	and	compared	PD-L1	staining	results	









showed	high	 sensitivity	 and	 specificity	 in	 identifying	 cases	with	³50%	of	 tumor	




















Currently,	 there	 are	 four	 drugs	 targeting	 the	 PD1/PD-L1	 axis	which	 have	 been	
approved	 by	 the	 Food	 and	 Drug	 Administration	 (FDA):	 two	 against	 PD-L1	










adenocarcinoma	 or	 squamous	 carcinoma	 on	 the	 basis	 of	 PD-L1	 expression	 on	
viable	tumor	cells,	evaluated	with	a	validated	assay.	Specifically,	the	KEYNOTE-010	
trial	 demonstrated	 that	 pembrolizumab	 prolonged	 the	 overall	 survival	 in	
previously	 treated	 patients	 whose	 tumors	 expressed	 PD-L1	 in	 at	 least	 1%	 of	
cells[15].	 Moreover,	 the	 KEYNOTE-024	 trial	 showed	 significantly	 longer	
progression-free	 survival	 and	 overall	 survival	 for	 previously	 untreated	 patients	
with	tumors	expressing	PD-L1	in	at	least	50%	of	cells[10].		
It	 is	 evident	 that	 the	 immunohistochemical	 evaluation	 of	 PD-L1	 expression	 on	















in	 patient	 selection	 for	 therapy	 in	 first	 and	 second	 line	 setting.	Moreover,	 we	
aimed	 at	 better	 defining	which	 value	 across	 core	 biopsies	 from	 the	 same	 case	
more	closely	reflects	the	actual	PD-L1	expression	status	and	how	many	biopsies	
are	needed	 for	 confident	classification	of	 tumors	 in	 terms	of	PD-L1	expression.	

























done	 using	 the	 TNM	 staging	 manual	 (7th	 edition).	 Patients	 demographics	 and	
clinical	data	were	retrieved	from	the	digital	archives.	











PD-L1	 (clone	 SP263,	 Ventana)	 on	 an	 automated	 staining	 platform	 (Benchmark	
ULTRA;	Ventana).	An	OptiView	DAB	IHC	Detection	Kit	(Ventana)	and	an	OptiView	
Amplification	 Kit	 (Ventana)	 were	 used	 according	 to	 the	 manifacturer’s	
recommendations	for	the	visualization	of	the	primary	anti	PD-L1	antibody.	
Stained	 sections	 were	 scanned	 using	 Ventana	 iScan	 HT	 and	 scored	 based	 on	
percentage	of	positive	tumor	cells	showing	membranous	positivity,	irrespective	of	















































































cases	 (12%)	 were	 positive	 in	 at	 least	 one	 core	 while	 210/239	 (88%)	 resulted	
negative.	 Of	 the	 positive	 cases,	 10	 (34%)	 showed	 100%	 concordance	 between	
available	 cores:	 among	 these,	 5	 had	 all	 5	 cores	 available,	 1	 case	 had	 	 4	 cores	
available	and	4	cases	had	3	cores	available.	Importantly,	19	(66%)	of	the	positive	
cases	showed	discordant	results	in	the	available	cores:	among	cases	with	5	cores	
available,	 6	were	 positive	 in	 just	 1	 core,	 4	were	 positive	 in	 2	 cores,	 3	 showed	
positivity	in	3	cores	and	4	had	4	cores	positive.	One	case	showed	PD-L1	positivity	
in	1	out	of	4	cores	and	1	case	stained	positive	in	3	out	of	4	cores	(Table	2B).		
When	 considering	 the	 two	 main	 histotypes,	 namely	 adenocarcinoma	 and	
squamous	cell	carcinoma,	positivity	in	at	least	one	core	was	seen	in	57/159	cases	











cores	was	 reached	 in	 7	 (39%)	 cases	while	 11	 cases	 (61%)	 showed	 discordance	
within	cores.	Among	positive	squamous	cell	carcinomas,	3/9	cases	(33%)	showed	














the	 highest	 concordance	 rate	 compared	 with	 corresponding	 whole	 sections	
(considered	as	gold	standard).	Overall,	at	1%	cutoff,	we	found	a	concordance	rate	
of	95.9%,	95.9%%,	86.5%	and	79.5%	for	maximum,	mean,	median	and	minimum	
value,	 respectively.	 Using	 50%	 cutoff,	 we	 found	 a	 concordance	 rate	 of	 95.6%,	
96.6%,	 96.2%	 and	 94.4%	 for	 maximum,	 mean,	 median	 and	 minimum	 value,	
respectively.	Discrepancies	were	due	to	the	heterogeneous	expression	of	PD-L1	in	

















For	 50%	 cutoff,	 we	 noted	 a	 progressive	 increment	 in	 terms	 of	 sensitivity	with	
increasing	number	of	cores	evaluated;	specifically,	we	found	AUC	and	sensitivity	>	
0.9	with	3	cores.	
We	 noted	 that,	 at	 50%	 cutoff,	 increasing	 numbers	 of	 cores	 corresponded	 to	 a	
decrease	of	specificity	(from	0.98	with	1	core	to	0.95	with	5	cores),	reflecting	the	
increasing	number	of	 false	positive	cases.	Overall,	considering	all	positive	cases	







of	 other	 PD-L1	 cutoffs	 on	 cores,	 comparing	 data	 to	 cases	 in	which	 tumor	 cells	
expressed	 PD-L1	 in	 ³	 50%	 of	 cells	 on	 the	 whole	 sections.	 Thus,	 we	 assessed		
sensitivity,	specificity	and	AUC	for	10%,	20%,	30%	and	40%	cutoff	values	related	
to	the	number	of	biopsies	analyzed	(table	5).	We	show	that,	at	20%	cutoff,	 less	













distant	 metastasis	 were	 metachronous,	 with	 a	 mean	 interval	 from	 time	 of	
resection	of	the	primary	tumor	of	19	months	(range:	8-29	months);	sites	of	distant	
















At	 1%	 cutoff,	 discrepancy	 in	 PD-L1	 expression	 was	 seen	 in	 3/9	 (33%)	 paired	








Table	1.	Clinical-pathological	 characteristics	of	patients	 in	 relation	with	PD-L1	
expression	on	whole	sections.		
	
















Patients	 268	 163	(61%)	 105	(39%)	 	 242	(90%)	 26	(10%)	 	
Age	 	 	 	 	 	 	 	
<	70	y	 121	(45%)	 76	(63%)	 45	(37%)	 0.54	 111	(92%)	 10	(		8%)	 0.47	
³	70	y	 147	(55%)	 87	(59%)	 60	(41%)	 	 131	(89%)	 16	(11%)	 	
Sex	 	 	 	 	 	 	 	
Male	 190	(71%)	 106	(56%)	 84	(44%)	 0.01	 170	(89%)	 20	(11%)	 0.48	
Female	 		78	(29%)	 57	(73%)	 21	(27%)	 	 72	(92%)	 6	(		8%)	 	
Histology	 	 	 	 	 	 	 	















Diameter	 	 	 	 	 	 	 	















N	Stage	 	 	 	 	 	 	 	










































	 Tot	 Neg	 Positive	
5	 191	 118	 15	 9	 13	 4	 32	
4	 29	 18	 2	 0	 2	 7	 	
3	 15	 6	 1	 2	 6	 	 	
2	 3	 3	 0	 0	 	 	 	
1	 1	 1	 0	 	 	 	 	
















	 Tot	 Neg	 Positive	
5	 191	 169	 6	 4	 3	 4	 5	
4	 29	 26	 1	 0	 1	 1	 	
3	 15	 11	 0	 0	 4	 	 	
2	 3	 3	 0	 0	 	 	 	
1	 1	 1	 0	 	 	 	 	











Value	across	cores	 Concordant	Cases	 False	Negative	 False	Positive	
Maximum	 257	(95.9%)	 4	(1.5%)	 7	(2.6%)	
Mean	 257	(95.9%)	 9	(3.4%)	 2	(0.7%)	
Median	 232	(86.5%)	 34	(12.8%)	 2	(0.7%)	
Minimum	 213	(79.5%)	 55	(20.5%)	 0	
	
PD-L1	³	50%	
Value	across	cores	 Concordant	Cases	 False	Negative	 False	Positive	
Maximum	 256	(95.6%)	 2	(0.7%)	 10	(3.7%)	
Mean	 259	(96.6%)	 8	(3%)	 1	(0.4%)	
Median	 258	(96.2%)	 7	(2.6%)	 3	(1.2%)	



















N.	of	cores	 N.	of	cases	 Sensitivity	 Specificity	 ROC	AUC	
1	Core	 268	 0.70	 0.98	 0.84	
2	Cores	 266	 0.78	 0.98	 0.88	
3	Cores	 262	 0.85	 0.98	 0.92	
4	Cores	 246	 0.91	 0.97	 0.94	
5	Cores	 215	 0.93	 0.98	 0.95	
	 	 PD-L1	³	50%	
N.	of	cores	 N.	of	cases	 Sensitivity	 Specificity	 ROC	AUC	
1	Core	 268	 0.77	 0.98	 0.87	
2	Cores	 266	 0.88	 0.98	 0.93	
3	Cores	 262	 0.92	 0.98	 0.95	
4	Cores	 246	 0.95	 0.96	 0.96	






	 10%	 20%	 30%	 40%	
Number	
of	cores	 SE	 SP	 AUC	 SE	 SP	 AUC	 SE	 SP	 AUC	 SE	 SP	 AUC	
1	core	 .96	 .91	 .94	 .96	 .95	 .96	 .88	 .96	 .92	 .81	 .97	 .89	
2	cores	 .96	 .88	 .92	 .96	 .93	 .94	 .92	 .95	 .93	 .88	 .96	 .92	
3	cores	 .96	 .85	 .91	 .96	 .89	 .93	 .96	 .92	 .94	 .92	 .95	 .93	
4	cores	 1	 .84	 .92	 .95	 .89	 .92	 .95	 .90	 .93	 .95	 .95	 .95	









































	 <	1%	 1-49%	 ≥50%	 Total	
<	1%	 40	 2	 0	 42	
1-49%	 5	 14	 2	 21	
≥50%	 2	 3	 7	 12	






	 <	1%	 1-49%	 ≥50%	 Total	
<	1%	 5	 2	 1	 8	
1-49%	 0	 1	 0	 21	
≥50%	 0	 0	 0	 0	



































The	 FDA	 recently	 approved	 the	 anti-PD1	 pembrolizumab	 as	 a	 single	 agent	 for	
patients	with	 tumors	expressing	PD-L1	 in	³	50%	of	neoplastic	cells	 for	 first	 line	
therapy	and	as	a	second	line	therapy	for	patients	whose	tumors	express	PD-L1	in	
at	 least	 1%	of	 cells[10,	 15].	 The	 vast	majority	of	 these	patients	have	advanced	
tumors	and	only	small	biopsies	are	often	available	for	PD-L1	determination.	It	is	
therefore	 of	 major	 importance	 to	 determine	 how	 many	 biopsies	 should	 be	
obtained	from	tumors	and	how	to	consider	the	results	of	PD-L1	staining	across	
tissue	cores	in	order	to	maximize	their	reliability	in	predicting	the	true	PD-L1	status	
of	 tumors.	 So	 far,	 only	 a	 few	 studies	 have	 addressed	 the	 issue	 of	 PD-L1	
heterogeneity	and	its	potential	role	in	tumor	misclassification,	given	the	possible	
discrepancies	between	biopsies	and	resection	specimens[17-19].		
Moreover,	 no	 attempts	 have	 been	made	 to	 harmonize	 biopsies	 and	 resection	
specimen	with	regard	to	PD-L1	expression	determination.	
In	 this	 study,	we	assessed	 the	heterogeneity	of	PD-L1	expression	 in	NSCLC	and	










Cohen’s	 κ	 value	 of	 0.53	 (moderate)	 and	 0,48	 (moderate)	 for	 ≥	 1%	 and	 ≥	 50%	
cutoffs,	respectively.	
These	 results	 mean	 that,	 in	 practice,	 if	 a	 single	 random	 biopsy	 was	 available,	
incorrect	 categorization	 might	 occur	 in	 up	 to	 7.9%	 and	 20%	 of	 patients	 with	
21	
	
advanced	NSCLC	eligible	 for	 first	and	second	 line	 therapy	with	pembrolizumab,	
respectively.	
In	general,	the	maximum	value	and	the	mean	value	across	cores	from	each	case	
showed	 the	 highest	 concordance	 rates	 with	 whole	 sections	 both	 at	 1%	 cutoff	
(95.9%	 for	 both	 values)	 and	 at	 50%	 cutoff	 (95.6%	 and	 96.6%	 respectively).	







Importantly,	with	 less	 than	 3	 cores,	 the	 sensitivity	was	 not	 satisfactory	 (<	 0.9)	
considering	 50%	 cutoff.	 However,	 by	 decreasing	 the	 cutoff	 on	 cores,	 their	








major	 importance.	 In	 this	 regard,	 it	should	be	noted	that	 in	our	cohort,	at	50%	
cutoff,	when	at	least	2	cores	were	positive,	the	risk	of	false	positive	cases	dropped	
to	1.2%.		
Kitazono	 et	 al.	 evaluated	 PD-L1	 expression	 using	 a	 polyclonal	 antibody	 (4059	
ProSci,	Poway,	CA)	on	70	diagnostic	biopsies	and	corresponding	surgical	specimen.	
They	 found	 positivity	 in	 38%	 of	 cases	 at	 1%	 cutoff	 with	 an	 overall	 good	
concordance	(92%)[19].	On	the	other	hand,	Ilie	et	al.,	by	evaluating	PD-L1	using	





















Another	 important	 question	 is	 related	 to	 the	 consistency	 of	 PD-L1	 expression	
between	primary	tumors	and	paired	metastasis,	as	possible	discrepancies	could	





50%	 cutoff,	 respectively[21].	 At	 variance	 with	 this	 study,	 however,	 we	 used	 a	








Currently,	 there	 are	4	 validated	assays	 for	PD-L1:	 2	 are	manufactured	by	Dako	
(Carpenteria,	CA)	and	are	optimized	for	use	with	the	detection	systems	developed	
for	 the	 Dako	 Link	 48	 staining	 platform	 while	 the	 other	 2	 assays	 have	 been	
developed	on	the	Ventana	BenchMark	platform.	Each		assay	was	developed	with	




poses	 serious	 difficulties	 regarding	 the	 application	of	 PD-L1	 testing	 in	 terms	of	
which	clone	and	platform	to	be	used	[22,	23].	The	fact	that	we	used	only	one	clone	




Another	 limitation	of	this	study	relies	 in	 its	retrospective	nature	and	the	use	of	
TMAs	as	surrogate	of	tumor	biopsies:	in	fact,	in	routine	diagnostics,	not	all	biopsies	






per	 case,	 each	 with	 an	 average	 dimension	 of	 1.5	mm2,	 	 and	 1-2	 transthoracic	










in	 regulating	 the	 extremely	 complex	mechanisms	 of	 immune	 response	 against	
tumors.	As	 recently	demonstrated	by	Yearley	et	al.,	 in	 fact,	PD-L2	expression	 is	
predictive	 of	 longer	 progression	 free	 survival	 in	 patients	 treated	 with	
pembrolizumab[24]:	it	is	reasonable	to	think	that	in	the	future	it	will	be	necessary	
to	 evaluate	 the	 status	 of	 other	molecules	 like	 PD-L2	 in	 order	 to	 better	 stratify	
patients.	
We	did	not	perform	PD-L2	evaluation	in	our	cohort	and	this	represents	another	





























the	number	of	cores	analyzed	and	 the	percentage	of	cells	positive	 for	PD-L1	 in	
each	core,	thus	allowing	the	clinicians	to	take	more	confident	decision	with	regard	
to	patient	selection	for	therapy.	
An	 accurate	 definition	 of	 the	 criteria	 to	 determine	 the	 PD-L1	 status	 of	 a	 given	
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